In this interview, News-Medical talks to Mr. Byrne about the crucial role of analytical services.
Septerna raises $150m in Series B funding round
A PTH1R agonist programme of Septerna is being developed to treat hypoparathyroidism. Credit: Kateryna Kon via Shutterstock.com. Biotechnology firm Septerna has raised $150m in a Series B funding round